atovaquone and rifampin: what the product label says
Read the product-label passage naming rifampin, with the source version, formulation and limitations.
The product label for dichlorphenamide names aspirin in its drug-interaction information. The complete selected section is reproduced below so that qualifications stay with the finding.
Dichlorphenamide โ TABLET โ ORAL
Labeled active ingredients: DICHLORPHENAMIDE. Routes: ORAL. Dosage forms: TABLET.
Section: 7.1 Aspirin and Other Salicylates
Carbonic anhydrase inhibitors, including dichlorphenamide, can cause metabolic acidosis [see Warnings and Precautions ( 5.2 , 5.4 )] , which can increase the risk of salicylate toxicity. Anorexia, tachypnea, lethargy, and coma have been reported with concomitant use of dichlorphenamide and high-dose aspirin. Therefore, concomitant use of dichlorphenamide and high-dose aspirin is contraindicated. Patients with concomitant use of dichlorphenamide and low-dose aspirin should be carefully monitored [see Contraindications ( 4 ) and Warnings and Precautions ( 5.2 )].
Read the full product label on DailyMed. Label version 1, dated 2025-11-25.
This passage applies to the labeled product and circumstances it describes. It must not be generalized to other routes or formulations. It does not independently validate CDIโs severity category, establish safety for an individual, or replace the full label. The stored interaction description and classification have not been changed by this article.
Automatic checks matched drug identities, retrieved and preserved the label, and checked the full quoted section with AI assistance on 2026-11-09. The public explanation uses a fixed template; model-written medical advice is not published. Independent clinical review has not been recorded.
Ask your pharmacist or prescriber whether the cited products, routes and circumstances apply to your medicines before changing treatment.
CDI checks every pair across up to 20 drugs โ backed by FDA and NIH data.
Drug interaction data sourced from U.S. FDA drug labeling via openFDA and the U.S. National Library of Medicine (NLM), National Institutes of Health. For informational purposes only. Always consult your pharmacist or physician before making any medication decisions.
Read the product-label passage naming rifampin, with the source version, formulation and limitations.
Read the product-label passage naming atenolol, with the source version, formulation and limitations.
Read the product-label passage naming disopyramide, with the source version, formulation and limitations.